Neuroservice and SynapCell are very pleased to announce the launch of a joint product, neurOsyn.
This new offer combines a unique in vitro and in vivo approach to document your compound’s effects on brain oscillations. Neuroservice has developed over the last 3 years in vitro Multi-Electrode Array measurements to record and to document 2D-oscillations in hippocampal slices in the beta, theta and gamma-ranges. Likewise, SynapCell has acquired for over 12 years a world-leading expertise in identifying and targeting disease-specific biomarkers in vivo, on translational animal models. This is performed by Cue, its EEG-based technology platform designed to objectively evaluate drug efficacy at the preclinical step.
The neurOsyn offer is proposed in two progressive steps.
Step#1: neurOsyn Exploratory
Consists in a 2 weeks quick screening test to determine if your compound is able to modulate in vitro 2D (slices – MEA) or in vivo 3D (brain – EEG) oscillations. If a trend is observed, then the compound gets a Go for step 2.
Step#2: neurOsyn Discovery
Allows for investigating over a few concentrations range the precise effect of your molecule on these in vitro and in vivo oscillations. This represent the unique opportunity to establish a robust biomarker related to your compound.
Working on CNS disorders?
Then do not miss the opportunity to catch a robust and translatable biomarker for your molecule.
NeurOsyn is the smoothest and fastest way for you to draw your compound signature and get the full picture on its potential.
NeurOsyn first got presented to the public at the SFN Neuroscience 2017 in Washington D.C in November 2017.